MedPath

Tagged News

Foundation Medicine Partners with Manifold to Enhance AI-Powered Drug Discovery Platform

AIPrecision MedicineDrug Discovery
  • Foundation Medicine announced a partnership with Manifold to integrate advanced AI capabilities into FoundationInsights®, enhancing its cloud-based data analytics platform for drug discovery and development.
  • The enhanced platform provides biopharmaceutical partners with AI-enabled natural language searches and faster insights from Foundation Medicine's proprietary dataset of over 800,000 patient genomic results.
  • Users can now rapidly identify patient groups and explore genomic alterations through intuitive AI tools, while technical users can perform customized analyses using Python and R programming languages.
  • The AI-powered FoundationInsights® is currently available to biopharmaceutical partners, with plans to launch a customized version for healthcare providers and health systems in 2026.

TET2 Clonal Hematopoiesis Identified as Biomarker for Enhanced Immunotherapy Response in Large-Scale Cancer Study

Precision Medicine
  • Caris Life Sciences and MD Anderson Cancer Center researchers identified TET2 clonal hematopoiesis as a promising biomarker for improved immune checkpoint inhibitor therapy response in solid tumors.
  • The study analyzed nearly 36,000 non-small cell lung cancer patients and over 25,000 colorectal cancer patients using Caris' extensive clinico-genomic database.
  • Laboratory models revealed that TET2 mutations enhance macrophage antigen presentation and shape immune dynamics within the tumor microenvironment.
  • These findings represent the first major observation directly linking clonal hematopoiesis to therapy outcomes in solid tumors, potentially guiding future therapy selection.

Chromatin Bioscience Partners with Purespring Therapeutics to Develop Precision Gene Therapy Promoters for Kidney Disease

Precision MedicineTargeted Therapy
  • Chromatin Bioscience has announced a research collaboration with Purespring Therapeutics to develop highly cell-selective synthetic promoters for precision nephrology gene therapies.
  • The partnership leverages Chromatin's chromatinLENS platform to create targeted promoters that enhance safety and efficacy of gene delivery for kidney disease treatments.
  • Purespring's lead program PS-002 targets IgA nephropathy through their proprietary GlomThera platform, which delivers genetic therapies directly to podocytes.
  • The collaboration represents a significant milestone in expanding Chromatin Bioscience's network of partnerships across the gene therapy landscape.

Guardant Health Partners with Zephyr AI to Advance Cancer Biomarker Discovery Through AI-Driven Precision Medicine

AIPrecision MedicineTargeted TherapyOncology
  • Guardant Health and Zephyr AI announced a strategic partnership to combine multimodal molecular data with AI technology for novel cancer biomarker identification and targeted therapy development.
  • The collaboration will integrate Guardant's real-world precision oncology data with Zephyr's proprietary AI platform to generate predictions of targeted cancer therapy response validated by clinical outcomes.
  • This partnership aims to accelerate biopharmaceutical research and development by providing actionable scientific intelligence for drug development, therapy selection, and response monitoring.
  • The initiative represents a convergence of advanced diagnostics, machine learning, and comprehensive real-world data to enable more precise and scalable oncology solutions for personalized cancer treatment.

Raffles Medical Group Partners with Gene Solutions to Streamline Cancer Clinical Trial Access in Southeast Asia

Precision MedicineTargeted TherapyOncology
  • Raffles Medical Group and Gene Solutions signed a Memorandum of Understanding on October 22, 2025, to streamline patient recruitment for oncology clinical trials in Southeast Asia.
  • The partnership will use Comprehensive Genomic Profiling to automatically screen patients for clinical trial eligibility, with the first study being KRYSTAL-7 for non-small cell lung cancer patients with KRAS G12C mutations.
  • Gene Solutions leverages Next Generation Sequencing technology through its K-4CARE test to decode cancer genetic profiles and identify patients who may respond to advanced treatments.
  • The collaboration aims to make cutting-edge cancer treatments more accessible and support equitable access to clinical trials across Vietnam and Southeast Asia.

AC Immune Publishes First-in-Class TDP-43 PET Tracer Data in Nature Communications, Advances to Phase 1 Trial

Precision Medicine
  • AC Immune SA announced publication in Nature Communications of preclinical data on ACI-19626, a first-in-class brain PET tracer for imaging TDP-43 pathology in neurodegenerative diseases.
  • The Morphomer-based tracer demonstrates high specificity for pathological TDP-43 aggregates with rapid brain uptake and complete washout, potentially enabling precision diagnosis of ALS, FTD, and LATE.
  • ACI-19626 has advanced to Phase 1 clinical trials with initial readout expected in Q4 2025, addressing the diagnostic challenge of differentiating TDP-43 proteinopathies.
  • The development could revolutionize diagnosis and treatment of multiple neurodegenerative diseases that share clinical features, potentially enabling earlier intervention before irreversible damage occurs.

Hebrew University Researchers Develop RIBOTAC Technology to Target Cancer-Linked TERRA RNA

Precision MedicineTargeted TherapyOncology
  • Researchers at Hebrew University of Jerusalem have engineered a novel RIBOTAC drug molecule that can precisely destroy TERRA, a long non-coding RNA implicated in cancer cell survival mechanisms.
  • The technology utilizes a guided missile approach to selectively target TERRA's unique G-quadruplex structure, recruiting cellular enzyme RNase L for specific RNA degradation without harming healthy molecules.
  • Testing in cancer cell lines including HeLa and U2OS cells demonstrated significant TERRA reduction and marked slowdown in cancer cell growth, particularly relevant for aggressive brain and bone tumors.
  • This breakthrough represents a paradigm shift from protein-targeted therapies to RNA-based treatments, potentially opening new therapeutic avenues for previously untargetable diseases.

MGI Tech and Eva Holding Group Partner to Bring First IVD-Certified High-Throughput Genetic Sequencer to Brazil

Precision Medicine
  • MGI Tech has partnered with Eva Holding Group to install the DNBSEQ-T7 genetic sequencer, marking the first IVD-certified high-throughput equipment available for clinical use in Brazil.
  • The collaboration aims to enhance cancer disease tracking accuracy and expand Brazilian patients' access to genomic technologies for precision medicine applications.
  • The partnership will particularly benefit oncology patients, rare disease diagnosis, and neonatal screening through advanced genomic sequencing capabilities including the 72-hour Genome service.

Accent Therapeutics Unveils Promising Preclinical Data for Novel Cancer Therapies ATX-295 and ATX-559 at Major Oncology Conference

Precision MedicineTargeted Therapy
  • Accent Therapeutics presented new preclinical data on two lead programs at the 2025 AACR-NCI-EORTC International Conference, demonstrating the potential of targeting genomic instability in cancer treatment.
  • ATX-295, a novel KIF18A inhibitor, showed enriched activity in ovarian and triple-negative breast cancer models with whole genome doubling, inducing dose-dependent tumor regression.
  • ATX-559, a first-in-class DHX9 inhibitor, demonstrated potent activity in preclinical models of microsatellite instability-high and BRCA-deficient cancers through selective cancer cell death.
  • Both experimental therapies are currently being evaluated in Phase 1/2 clinical trials, representing a biomarker-driven approach to precision cancer medicine.

First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Including Ovarian Cancer

NCT06799065RecruitingPhase 1
Accent Therapeutics
Posted 3/21/2025

First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers

NCT06625515RecruitingPhase 1
Accent Therapeutics
Posted 10/11/2024

Gene Expression Test Reduces Need for Invasive Lymph Node Biopsies in Early-Stage Melanoma Patients

Precision MedicineOncology
  • A large multicenter trial involving nearly 1,800 melanoma patients demonstrated that a gene expression profile test can accurately identify patients with low risk of lymph node metastasis.
  • The test classified 37% of patients as low risk, with only 7.1% of these patients having cancer in their lymph nodes compared to 23.8% in the high-risk group.
  • The findings could help reduce unnecessary sentinel lymph node biopsies, sparing patients from invasive surgery while maintaining treatment accuracy.
  • The test combines genetic markers with clinical factors like tumor thickness and patient age to provide personalized risk assessment for treatment decisions.

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.